Polaris Group

Polaris Group

TTWSE:6550
13.05
TWD
-0.10
(-0.76%)
-5.20EPS
23.34BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
0.01
0.02
0.01
0.01
0.14
0.05
0.09
Basic EPS, GAAP
-5
-5.4
-4.37
-3.68
-3.81
-2.46
-1.01
-1.09
-1.57
-2.01
-3.35
-5.1
-5.2
Free Cash Flow per Basic Share
-11.9
-7.6
-4.83
-2.99
-3.03
-2.37
-0.98
-1.09
-1.5
-2.14
-4.94
-4.14
-3.68
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.56
4.66
0.91
3.48
2.1
5.52
4.41
10.03
11.68
9.95
8.69
6.16
5.07
Tangible Book Value per Share
-0.68
4.49
0.82
3.46
2.1
5.52
4.41
10.03
11.68
7.07
5.86
5.27
4.44
Basic Weighted Avg Shares
164
187
225
244
271
337
653
681
733
743
747
771
725
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
9
15
6
7
107
41
68
Operating Margin (%)
- -
- -
- -
- -
- -
- -
-7,205.72
-4,866.15
-17,977.12
-24,805.8
-2,462.4
-7,090.07
-3,743.03
Depreciation Expense
59
107
129
114
111
138
133
154
144
144
315
376
405
Net Income, GAAP
-820
-1,008
-982
-898
-1,032
-830
-660
-740
-1,150
-1,492
-2,503
-3,927
-3,769
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
-7,016.2
-4,923.12
-17,866.64
-19,948.26
-2,338.92
-9,672.25
-5,546.47
Working Capital
893
70
-634
265
-659
2,403
1,601
5,913
7,289
4,146
2,856
2,431
2,069
LT Debt
- -
399
707
708
210
224
169
139
262
452
1,800
2,239
2,283
Total Equity
695
1,106
215
1,008
641
3,610
2,882
7,214
8,674
7,672
6,771
5,296
4,541
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-148.74
-146.91
-125.22
-39.05
-20.34
-14.67
-14.48
-18.56
-35.5
-65.5
-81.61

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
108
98
81
LT Borrowings
2,089
2,116
2,122
LT Finance Leases
150
167
160
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
860
860
895
Market Capitalization
51,478
31,698
23,339

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,017
2,398
2,570
Cash, Cash Equivalents & STI
2,743
2,101
2,304
Accounts Receivable, Net
3
41
4
Inventories
122
108
112
Total Current Liabilities
586
500
502
Payables & Accruals
- -
- -
- -
ST Debt
108
98
81
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
82.09%
25.1%
-21.78%
Free Cash Flow
16.11%
45.55%
-13.57%
Net Income, GAAP
18.56%
44.37%
56.92%
Sales/Revenue/Turnover
- -
257.41%
-62.05%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
28
32
11
36
107
2025
8
8
18
6
41
2026
37
7
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.56
-0.77
-1
-2.16
-3.35
2025
-0.86
-1.16
-0.89
-4.2
-5.1
2026
-0.64
-0.98
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Samuel Chen
Full Time Employees
674
Sector
Health technology
Industry
Biotechnology
Address
P.O. Box 309, Ugland House Taipei TAO Taiwan KY1-1104
IPO Date
Jun 6, 2022
Business
Polaris Group (TWSE: 6550) is a Cayman Islands-incorporated multinational biotechnology company that engages in the research, development, manufacture, and sale of novel anti-cancer therapies, peptide drugs, active pharmaceutical ingredients (API), generics, and provides contract development and manufacturing organization (CDMO) services, drug testing, and other biotechnology services. The company offers its lead drug candidate Pegargiminase (ADI-PEG 20), a biologic targeting arginine deprivation for late-stage clinical development in cancers including hepatocellular carcinoma, malignant pleural mesothelioma (MPM), pancreatic cancer, non-small cell lung cancer, melanoma, and acute myeloid leukemia; through subsidiaries such as Genovior Biotech Corporation, it manufactures sterile injectables, fully synthetic peptides, and specialty dosage forms, while DesigneRx Pharmaceuticals, Inc., Nanotein Technologies, Inc., DesigneRx Pharmaceuticals (Chengdu), Inc., and Polaris Pharmaceuticals, Inc. support structure-based drug design, cGMP production in Northern California and China, and clinical studies at top-tier cancer centers worldwide. Polaris Group operates across North America, Asia, and pursues global markets including Latin America and the Gulf Cooperation Council region, with headquarters effectively in Taiwan and key facilities in the United States and China; founded on February 9, 2006, it targets pharmaceutical companies, healthcare providers, and patients with hard-to-treat cancers. Recent developments include Genovior Biotech's expansion of sterile injection capacity for global supply of synthetic peptides and injectables; a non-exclusive commercialization agreement with MNR Therapeutics for Fulvestrant in the GCC region in November 2025; Polaris Pharmaceuticals Inc.'s exclusive in-licensing partnership with Bioprofarma Bagó in July 2025 to introduce ADI-PEG 20 in Argentina and other Latin American markets; and the U.S. FDA's entry into substantive review of the Biologic License Application for ADI-PEG 20, indicated with platinum and pemetrexed for non-epithelioid MPM, following full submission in June 2025.